IFNγ exhibits potent antitumor effects and plays important roles in the innate immunity against cancer. However, the mechanisms accounting for the antiproliferative effects of IFNγ still remain to be elucidated. We examined the role of Mnk1 (MAPK-interacting protein kinase 1) in IFNγ signaling. Our data demonstrate that IFNγ treatment of sensitive cells results in engagement of Mnk1, activation of its kinase domain, and downstream phosphorylation of the cap-binding protein eIF4E on Ser-209. Such engagement of Mnk1 plays an important role in IFNγ-induced IRF-1 (IFN regulatory factor 1) gene mRNA translation/protein expression and is essential for generation of antiproliferative responses. In studies aimed to determine the role of Mnk1 in the suppressive effects of IFNs on primitive hematopoietic progenitors, we found that siRNA-mediated Mnk1/2 knockdown results in partial reversal of the suppressive effects of IFNγ on human CD34+-derived myeloid (CFU-GM) and erythroid (BFU-E) progenitors. These findings establish a key role for the Mnk/eIF4E pathway in the regulatory effects of IFNγ on normal hematopoiesis and identify Mnk kinases as important elements in the control of IFNγ-inducible ISG mRNA translation.

The only known member of the Type II IFN family, IFNγ, plays an important role in the innate and adaptive immunity against microbial and viral infections and exhibits potent antitumor effects (1–4). IFNγ is a cytokine mainly secreted by T lymphocytes, activated natural killer cells, and antigen-presenting cells such as macrophages and dendritic cells (5, 6) and is known to elicit pleiotropic biological effects on cells and tissues. This cytokine enhances the activity of natural killer cells, facilitates class switching, and regulates immunoglobulin production by B cells (5–7). In addition, it regulates survival and proliferation of T cells, modulates the activity of antigen presenting cells and, under certain circumstances, can promote differentiation of several distinct cell types (5–7). Importantly, IFNγ facilitates immune responses to tumor cells, although it also inhibits angiogenesis and exerts direct anti-proliferative effects on a number of tumor cells (8). Thus, considering the broad effects of IFNγ, understanding the cellular mechanisms that regulate its biological effects is highly relevant in advancing our overall understanding of the mechanisms of innate immunity against cancer and viral infections.

Previous studies have established that IFNγ transduces signals by binding to its cell surface receptor, which is composed of two distinct subunits; the IFNγ receptor 1 and 2 chains, which are constitutively associated with the JAK family members JAK1 and JAK2 (reviewed in Refs. 2 and 3). Binding of IFNγ to its receptor results in interactions between the receptor chains leading to the phosphorylation of the STAT1 transcriptional activator, followed by its dimerization, translocation to the nucleus, and activation of gene transcription by IFNγ-activated sequences (GAS)2 (2, 3). Beyond the classic JAK-STAT pathway, the transcriptional response to IFNγ also involves IFNγ-activated transcription elements (9) that are controlled by the transcription factor CCAAT enhancer-binding protein-β. Notably, the activity of CCAAT enhancer-binding protein-β is positively regulated by the MAP kinases Erk1 and Erk2 (10). There has been also some previous evidence implicating protein kinase pathways in the generation of cellular responses to IFNγ. The phosphatidylinositol 3-kinase regulates transcriptional regulation by IFNγ (11, 12), whereas the Akt/mTOR pathway plays an important role downstream of phosphatidylinositol 3-kinase, promoting mRNA translation of ISGs (13, 14). PKC family members PKCδ, PKCθ, and PKCe have been also shown to play important roles in IFNγ signaling (11, 15, 16). Additionally there is evidence for important functional roles for MAPK pathways in the induction of IFNγ responses (17–20).

We determined whether Mnk(s) (MAPK-interacting protein kinases) 1 and 2 are activated during engagement of the Type
Mnk Kinases in the Generation of IFNγ Responses

II IFN receptor and participate in the generation of IFNγ responses. Mnk1 is a downstream effector for both the p38 MAPK and Erk1/2 pathways and along with the related Mnk2 regulates phosphorylation of eIF4E (21, 22). Our data show that IFNγ treatment results in activation of Mnk1 and its downstream target eIF4E in an Mek/Erk-dependent manner. In studies using dual Mnk1/Mnk2 knock-out cells, we found that Mnk activity is essential for IFNγ-dependent mRNA translation of IRF-1 (interferon regulatory factor 1) and plays a critical role in the generation of growth inhibitory responses by the Type II IFN receptor. Altogether, our findings identify Mnk1 as a novel element required for mRNA translation of ISGs and generation of IFNγ antiproliferative responses.

MATERIALS AND METHODS

Antibodies, Cell Lines, and Reagents—The antibodies against p-Mnk1 (Thr-197/202), Mnk1, p-eIF4E (Ser-209), eIF4E, p-Erk1/2 (Thr-202/Tyr-204), Erk1/2, pSTAT1 (Tyr-701), and p-STAT1 (Ser-727) were obtained from Cell Signaling Technology (Danvers, MA). The antibodies against STAT1 and IRF-1 were obtained from Santa Cruz Biotechnology (Dallas, TX). The antibody against GAPDH was obtained from Millipore (Billerica, MA). Human and mouse IFNγ were obtained from PBL Interferon Source (Piscataway, NJ). U937 cells were grown in RPMI-1060 supplemented with 10% (v/v) fetal bovine serum and antibiotics. CD34+ cells were obtained from either Lonza (Basel, Switzerland) or Stemcell Technologies (Vancouver, Canada). Immortalized Mnk1−/−, Mnk2−/−, Mnk1/Mnk2−/− MEFs, and Mnk1/Mnk2−/− MEFs were cultured in DMEM supplemented with 10% (v/v) fetal bovine serum and antibiotics. The Mnk inhibitor CGP57380 and the Mek1/2 inhibitor U0126 were obtained from Calbiochem (Darmstadt, Germany). The siRNAs targeting human Mnk1 and Mnk2 as well as nontargeting siRNAs were obtained from Dharmacon.

Cell Lysis and Immunoblotting—The cells were treated with IFNγ (10^3 or 10^4 IU/ml) for the indicated times and were then lysed in phosphorylation lysis buffer as described in our previous studies (23, 24). In experiments using pharmacological inhibitors, the cells were pretreated with CGP57380 (5–10 μM) or U0126 (10 μM) for 1 h followed by IFNγ treatment for the indicated time in the continuous presence of the inhibitors; the cells were then lysed in phosphorylation lysis buffer. Immunoblotting was performed using an ECL method, as in our previous studies (25–27).

Luciferase Reporter Assay—Mnk1/2−/+ , Mnk1−/− , Mnk2−/− , and Mnk1/2−/− MEFs were transfected with an 8× GAS luciferase construct (containing a luciferase reporter gene with eight GAS elements linked to a minimal prolactin promoter) and a constitutive β-galactosidase expression vector using the SuperFect transfection reagent according to the protocol of the manufacturer (Qiagen). The 8× GAS construct was kindly provided by Dr. Christofer Glass (University of California, San Diego, CA) (28). 48 h post-transfection, the triplicate cultures were either left untreated or treated with mouse IFNγ (1,000 units/ml) for 6 h. The cells were then lysed, and the luciferase activity was measured as per the manufacturer’s instructions (Promega, Madison, WI) described in previous studies (23). The luciferase activity was then normalized utilizing the β-galactosidase activity for each sample.

Quantitative RT-PCR—The Mnk1/2−/+ , Mnk1−/− , Mnk2−/− , and Mnk1/2−/− MEFs were either left untreated or were with IFNγ (1,000 units/ml) for 6 h and RNA was isolated using the RNeasy kit (Qiagen). Cellular mRNA was reverse transcribed into cDNA using the Omniscript RT kit and oligo(dt) primer (Qiagen) as described previously (16). Quantitative PCR was carried out as described previously (14). Commercially available FAM-labeled probes and primers (Applied Biosystems) to determine Ifr-1 mRNA expression were used. GAPDH was used for normalization. The mRNA amplification was calculated as described previously (14), and the data were plotted as the fold increase as compared with untreated samples.

Isolation of Polysomal Fractions—The Mnk1/2−/+ , Mnk1−/− , Mnk2−/− , and Mnk1/2−/− MEFs were treated with mouse IFNγ (1,000 units/ml) for 48 h, and polysomal fractionation was performed as in our previous studies (13, 24).

Hematopoietic Progenitor Cell Assays—CD34+ cells were transfected with either control nontargeting siRNA or siRNA specific to human Mnk1 and/or Mnk2 (Dharmacon, Lafayette, CO). In some experiments the cells were also treated with the Mnk inhibitor CGP57380 (5 μM) or diluent control DMSO. The cells were then cultured in a methylcellulose assay system in the absence or presence of human IFNγ (1,000 units/ml) for 14 days, and erythroid (BFU-E) or myeloid (CFU-GM) colonies were scored as described previously (27, 29). In the experiments to assess the effects of Mnk inhibition on leukemic CFU-L progenitors, U937 cells were transfected with either control nontargeting siRNA or siRNAs targeting Mnk1, Mnk2, or both or treated with either DMSO or CGP57380 (2.5 μM). The cells were then cultured in a methylcellulose assay system in the absence or presence of human IFNγ (1,000 units/ml) for 7 days, and colony-forming units were scored as described previously (30).

RESULTS

In initial studies we examined whether IFNγ induces phosphorylation/activation of Mnk1. For these, sensitive U937 cells were treated with human IFNγ for different times, and cell lysates were analyzed by SDS-PAGE and immunoblotted with an antibody that recognizes the phosphorylated/activated form of Mnk1. IFNγ treatment resulted in rapid phosphorylation/activation of Mnk1, which was noticeable at 10 min and was still detectable 50 min post-IFNγ treatment (Fig. 1A), suggesting the involvement of this kinase in IFNγ signaling. We also examined whether IFNγ treatment regulates phosphorylation of the downstream effector of Mnk1, eIF4E, at Ser-209, which is the Mnk phosphorylation site in other systems (31–34). As shown in Fig. 1B, IFNγ treatment of U937 cells resulted in phosphorylation of eIF4E (Fig. 1B). To determine whether Mnk activity is essential for Type II IFN-dependent phosphorylation of eIF4E, we examined whether such induction is blocked in immortalized MEFs from mice with targeted disruption of both the Mnk1 and Mnk2 genes (34). Mnk1/2−/+ and Mnk1/2−/− MEFs were serum-starved and then treated with mouse IFNγ for different times. As seen
in Fig. 2A, IFNγ treatment resulted in strong phosphorylation of eIF4E in Mnk1/2+/− MEFs, whereas this phosphorylation was not inducible in the Mnk1/2−/− MEFs (Fig. 2A). Consistent with this, in experiments in which the effects of pharmacological inhibition of Mnk were evaluated in U937 leukemic cells, we found that the IFNγ-dependent phosphorylation of eIF4E is Mnk1/2-dependent (Fig. 2B).

We subsequently sought to define upstream signaling events required for activation of Mnk1 and eIF4E during engagement of the Type II IFN receptor. Mnk1 has been shown to be phosphorylated by the Erk1 and Erk2 kinases in response to various stimuli (31–33). We examined the phosphorylation of Mnk1 and eIF4E in response to IFNγ treatment.

**Mnk Kinases in the Generation of IFNγ Responses**

**FIGURE 1.** IFNγ-mediated engagement of Mnk1 and eIF4E. A, U937 cells were treated with human IFNγ for the indicated times. Total lysates were separated by SDS-PAGE and immunoblotted with an antibody against phosphorylated Mnk1 (Thr-197/202). The same blot was stripped and reprobed with an antibody against total Mnk1. The signals for pMnk1 and total Mnk1 from three independent experiments (including the one shown in A) were quantitated by densitometry, and the intensity of pMnk1 relative to total Mnk1 expression was calculated. The data are expressed as the means of ratios of pMnk1 to Mnk1 levels ± S.E. for each experimental condition.

**FIGURE 2.** Mnk1/2 is required for IFNγ-mediated engagement of eIF4E. A, Mnk1/2+/− and Mnk1/2−/− MEFs were serum-starved overnight and treated with mouse IFNγ for the indicated times. Equal amounts of lysates were separated by SDS-PAGE followed by immunoblotting with an antibody against phosphorylated eIF4E (Ser-209). The same blot was stripped and reprobed with an antibody against total eIF4E. B, U937 cells were incubated with either DMSO or CGP57380 for 60 min and were then treated with human IFNγ for the indicated times. Equal amounts of lysates were separated by SDS-PAGE and then immunoblotted with an antibody against phosphorylated eIF4E (Ser-209). The blot was then stripped and reprobed with an antibody against total eIF4E.

**FIGURE 3.** IFNγ-mediated engagement of Mnk1 and eIF4E is Mek/Erk-dependent. A, U937 cells were incubated with either DMSO or U0126 for 60 min and were then treated with human IFNγ for the indicated times. Equal amounts of protein were separated by SDS-PAGE and then immunoblotted with antibodies against phosphorylated Erk1/2 (Thr-202/Tyr-204). The blot was then stripped and reprobed with an antibody against total Erk1/2. B, U937 cells were incubated with either DMSO or U0126 for 60 min and were then treated with human IFNγ for the indicated times. Equal amounts of lysates were separated by SDS-PAGE and then immunoblotted with antibodies against phosphorylated Mnk1 (Thr-197/202) or against phosphorylated eIF4E (Ser-209). The respective blots were then stripped and reprobed with antibodies against total Mnk1 or total eIF4E.
phorylation of Mnk1 and Mnk2 in U937 cells in the presence of the Mek/Erk inhibitor U0126. U937 cells were pretreated with either DMSO (control) or U0126 and then treated with IFN for the indicated times. IFN has been shown to result in the engagement of Erk1 and Erk2 in various systems (35, 36). As expected, U0126 inhibited IFN-dependent phosphorylation/activation of Erk1/2 (Fig. 3A). In DMSO pretreated cells, Mnk1 and eIF4E were phosphorylated by IFN, whereas in U0126-treated cells, the activation of Mnk1 and eIF4E was suppressed (Fig. 3B), indicating that the Mek/Erk pathway is required for IFN-mediated activation of Mnk1/eIF4E.

We next examined the role of Mnk1 as a putative mediator of IFN signaling events. We initially determined whether Mnk1 plays a role in the regulation of phosphorylation/activation of STAT1 and IFN-regulated gene transcription. STAT1 phosphorylation by IFN on both Tyr-701 and Ser-727 was intact in the absence of either Mnk1 or Mnk2 and in the absence of both Mnk1 and Mnk2 (Fig. 4B). Consistent with this, transcriptional activation via GAS elements was intact in luciferase promoter assays (Fig. 4C), establishing that Mnk kinases do not play roles in the control of IFN-induced STAT1 activation or gene transcription. Interestingly, there was some increase seen in the IFN-induced serine phosphorylation of STAT1 (Fig. 4A), suggesting a compensatory effect, but the precise mechanism and relevance of this finding remains to be defined in future studies.

IFN up-regulates the expression of the IRF-1, which plays an important role in mediating the biological effects of IFN.

**FIGURE 4.** Mnk1 and Mnk2 are not required for IFN-mediated engagement of STAT1 or activation of transcription via GAS elements. A, Mnk1/2+/+, Mnk1−/−, Mnk2−/−, and Mnk1/2−/−MEFs were treated with IFN for the indicated times. Equal amounts of total cell lysates were separated by SDS-PAGE and immunoblotted with antibodies against phosphorylated STAT1 (Ser-727). The blot was stripped and reprobed with antibody against total STAT1. The signals for pSTAT1 (Ser-727) and total STAT1 from three independent experiments (including the one shown in A) were quantitated by densitometry, and the intensity of pSTAT1 (Ser-727) relative to total STAT1 expression was calculated. The data are expressed as the means of ratios of pSTAT1(S727) to STAT1 levels ± S.E. for each experimental condition. B, Mnk1/2+/+, Mnk1−/−, Mnk2−/−, and Mnk1/2−/− MEFS were treated with IFN for the indicated times. Equal amounts of total cell lysates were separated by SDS-PAGE and immunoblotted with antibodies against phosphorylated STAT1 (Tyr-701). The blot was stripped and reprobed with antibody against total STAT1. The signals for pSTAT1 (Tyr-701) and total STAT1 from three independent experiments (including the one shown in B) were quantitated by densitometry, and the intensity of pSTAT1 (Tyr-701) relative to total STAT1 expression was calculated. The data are expressed as the means of ratios of pSTAT1 (Tyr-701) to STAT1 levels ± S.E. for each experimental condition. C, Mnk1/2+/+, Mnk1−/−, Mnk2−/−, and Mnk1/2−/− MEFS were transfected with an 8× GAS luciferase construct. 48 h post-transfection, the cells were incubated with or without IFN for 6 h. The cells were then harvested and assayed for luciferase activity. The data are expressed as fold increases in luciferase activity in response to IFN treatment over control untreated cells and represent the means ± S.E. of four independent experiments.
A major target for Mnk kinases is the initiation factor eIF4E, mediators of growth factor and pro-inflammatory signals (37). Extensive work over the years has established the relevance of Mnk kinases in stress-activated signaling cascades and as mediators of growth factor and pro-inflammatory signals (37). A major target for Mnk kinases is the initiation factor eIF4E, which undergoes Mnk-mediated phosphorylation on serine
Phosphorylation of eIF4E at this site has been shown in different studies to be of importance in the initiation of mRNA translation for certain genes, as well as for oncogenic transformation and malignant cell proliferation (38–42). Mnk kinases have been also implicated in the production of TNF, IL-6, and monocyte chemoattractant protein-1 in response to LPS (43, 44), whereas more recent studies have provided evidence that, under certain circumstances, Mnk1 is involved in cap-independent translation (45, 46). The importance of the Mnk/eIF4E pathway in tumorigenesis was definitively established in recent work using knock-in mice expressing a mutant form of eIF4E, which cannot undergo phosphorylation on serine 209 (47). These studies demonstrated that phosphorylation on this site is required for tumorigenesis in a prostate cancer mouse model (47). Remarkably, eIF4E phosphorylation on serine 209 was also found to correlate with a high Gleason score, high levels of MMP3 expression, and disease progression in prostate cancer patients (47). Other recent studies demonstrated that Mnk1/2 activity is required for tumor development in the Lck-Pten mouse model (48), underscoring the relevance of the Mnk/eIF4E pathway in malignant tumor development.

The only Type II IFN, IFNγ, exhibits pleiotropic biological functions, including immunomodulatory, antitumor, and anti-inflammatory activities. IFNγ is a key cytokine involved in the activation of immune cells and the suppression of tumor growth. The induction of IFNγ expression in response to viral infections or other stimuli leads to the activation of various signaling pathways, including the JAK-STAT and PI3K-Akt pathways, which ultimately result in the upregulation of IFNγ-dependent genes.

**FIGURE 6.** Mnk kinases are required for IFNγ-induced IRF1 mRNA translation. A, Mnk1/2+/+ and Mnk1/2−/− MEFs were either left untreated or treated with mouse IFNγ. The cells were subjected to hypotonic lysis followed by separation on a 10–50% sucrose gradient, and the optical density at 254 nm (OD 254) was recorded. The optical density at 254 nm is shown as a function of gradient depth for each treatment. B, IRF-1 mRNA expression in the polysomal fractions was determined by quantitative RT-PCR, using GAPDH for normalization. The data are expressed as fold increases in the IFNγ-treated samples over untreated samples and represent the means ± S.E. of three independent experiments.
tiviral activities (49). This cytokine plays key roles in the generation of antineoplastic activities and in the immune surveillance against tumors (49). Interestingly, IFN-γ has also been implicated in diverse pathophysiological states, ranging from bone marrow failure (50) to arteritis (51) or atherosclerosis (52). Such a functional diversity of responses suggests the ex-

FIGURE 7. Mnk1 and Mnk2 in IFN-γ-induced mRNA translation. A, Mnk1/2+/−, Mnk1−/−, and Mnk2−/− MEFS were either left untreated or treated with mouse IFN-γ. The cells were subjected to hypotonic lysis followed by separation on a 10–50% sucrose gradient, and the optical density at 254 nm (OD 254) was recorded. The optical density at 254 nm is shown as a function of gradient depth for each treatment. B, IRF-1 mRNA expression in the polysomal fractions was determined by quantitative RT-PCR, using GAPDH for normalization. The data are expressed as fold increases in the IFN-γ-treated samples over untreated samples and represent the means ± S.E. of four independent experiments.

FIGURE 8. Mnk kinases mediate the antiproliferative effects of IFN-γ on U937 cells. A, U937 cells were incubated in clonogenic assays in methylcellulose with or without human IFN-γ, in the presence of DMSO or CGP57380, as indicated. Leukemic CFU-L colonies were scored, and the data are expressed as percentages of control DMSO treated colonies and represent the means ± S.E. of three independent experiments. Paired t test analysis showed p = 0.00275 for the combination of DMSO and IFN-γ versus the combination of CGP57380 and IFN-γ. B, U937 cells were transfected with the indicated siRNAs and plated in a methylcellulose assay system in the absence or presence of human IFN-γ. The data are expressed as percentages of control siRNA transfected cell-derived colony formation and represent the means ± S.E. of six independent experiments. Paired t test analysis showed p = 0.00019 for the combination of control siRNA and IFN-γ versus the combination of Mnk1-specific siRNA and IFN-γ; p = 0.00011 for the combination of control siRNA and IFN-γ versus the combination of Mnk2-specific siRNA and IFN-γ; and p = 0.00073 for the combination of control siRNA and IFN-γ versus the combination of Mnk1- and Mnk2-specific siRNAs and IFN-γ. UT, untreated.
Mnk Kinases in the Generation of IFNγ Responses

A

CFU-GM

BFU-E

P = 0.0022

P = 0.0102

DMSO

CGP57380

P = 0.0031

P = 0.0151

Control siRNA

Mnk1 siRNA

Mnk2 siRNA

Mnk1/2 siRNA

P = 0.0026

P = 0.0084

Control siRNA

Mnk1 siRNA

Mnk2 siRNA

Mnk1/2 siRNA

P = 0.0084

P = 0.0110

P = 0.0198

FIGURE 9. Mnk kinases are essential for the generation of the myelosuppressive effects of IFNγ. A, CD34+ cells derived from normal bone marrow were incubated in clonogenic assays in methylcellulose with or without human IFNγ, in the presence of DMSO or CGP57380, as indicated. CFU-GM and BFU-E progenitor colonies were scored after 14 days in culture. The data are expressed as percentages of control colony formation from DMSO-treated cells and represent the means ± S.E. of five independent experiments. Paired t test analysis showed p = 0.0022 for the combination of DMSO and IFNγ versus the combination of CGP57380 and IFNγ for CFU-GM colonies. Paired t test analysis showed p = 0.0102 for the combination of DMSO and IFNγ versus the combination of CGP57380 and IFNγ for BFU-E colonies. B, CD34+ cells derived from normal bone marrow were transfected with the indicated siRNAs and were then plated in a methylcellulose assay system, in the absence or presence of human IFNγ, as indicated. CFU-GM and BFU-E progenitor colonies were scored after 14 days in culture. The data are expressed as percentages of control colony formation from control siRNA transfected cells and represent the means ± S.E. of five independent experiments. Paired t test analysis showed p = 0.0031 for the combination of control siRNA and IFNγ versus the combination of Mnk1 siRNA and IFNγ for CFU-GM colonies; and p = 0.0084 for the combination of control siRNAs and IFNγ versus the combination of Mnk1 siRNA and IFNγ for BFU-E colonies. Paired t test analysis showed p = 0.0026 for the combination of control siRNA and IFNγ versus the combination of Mnk2 siRNA and IFNγ for CFU-GM colonies; and p = 0.011 for the combination of control siRNAs and IFNγ versus the combination of Mnk2 siRNA and IFNγ for BFU-E colonies. Paired t test analysis showed p = 0.0151 for the combination of control siRNA and IFNγ versus the combination of Mnk1 and Mnk2 siRNAs and IFNγ for CFU-GM colonies and p = 0.0198 for the combination of control siRNAs and IFNγ versus the combination of Mnk1 and Mnk2 siRNAs and IFNγ for BFU-E colonies. UT, untreated.

and to play an important role in mediating the antiproliferative effects of IFNγ in malignant mesothelioma cell lines (57) and in oligodendrocyte progenitor cells (58).

Our findings establish that the function of Mnk kinases is essential for generation of the suppressive effects of IFNγ in normal human CD34+ derived erythroid (BFU-E) and myeloid (CFU-GM) progenitors, defining a critical and essential role for the pathway in the regulation of normal hematopoiesis by IFNγ. Based on our data, these regulatory effects of the Mnk pathway may reflect the requirement for Mns in IRF-1 mRNA translation, because previous studies have also shown that IRF-1 plays an important role in mediating IFNγ-induced inhibitory responses in normal human hematopoietic CD34+ progenitor cells (59). Thus, as in the case of Type I IFNs (60), Mnk kinases appear to play key and essential roles in mRNA translation of certain ISGs and generation of signals required for antiproliferative responses and the suppression of hematopoiesis. The requirement of the Mnk/eIF4E pathway in the generation of IFN-dependent antiproliferative responses and suppressive effects on normal and leukemic hematopoiesis is

istence and coordination of multiple cellular pathways activated by the Type II IFN receptor. It should be noted that the Type II IFN receptor is structurally and functionally distinct from the Type I IFN receptor, and IFNγ has only minimal identity with the family of Type I IFNs (53).

In the current study, we examined whether Mnk kinases are engaged in signaling by the Type II (IFNγ) receptor and their functional relevance in the induction of Type II IFN-mediated mRNA translation of regulated genes and generation of IFNγ responses. Our data demonstrate that Mnk1 is phosphorylated/activated in an IFNγ-inducible manner in sensitive cells and regulates downstream phosphorylation of eIF4E on serine 209. In studies using double knock-out MEFs for both Mnk1 and Mnk2, we identified a requirement for Mns in the phosphorylation/activation of eIF4E. Moreover, mRNA translation of the IRF-1 gene and expression of the IRF-1 protein was defective in Mnk1 and/or Mnk2 MEFs, indicating a requirement for the Mnk pathway in IRF-1 protein expression. Notably, IRF-1 has been shown to promote induction of anti-tumor activities in a variety of tumors (54–56)
in some ways surprising, because there is extensive evidence implicating this pathway in tumorigenesis and malignant cell proliferation (38–42, 47, 48). It is possible that, in contrast to growth factors and oncogenes, this pathway is used in a selective way by the Type II IFN receptor for mRNA translation of genes, such as IRF-1, that mediate growth inhibitory responses. Coordination of gene transcription by IFN-activated JAK-STAT pathways and IFN-dependent engagement of the Mnk/eIF4E pathway may lead to expression of proteins that mediate growth suppression. Importantly, it is possible that the Type II IFN receptor competes with growth factor receptors for use of this pathway, depriving them of a pathway essential for mitogenic responses and tumorigenesis.

In addition to eIF4E, Mns are known to regulate the function of several other signaling proteins and effectors. Mnk1 is implicated in the phosphorylation of the heterogenous ribonuclear protein A1 (61), as well as PSF (the polyribosumidine tract-binding protein-associated splicing factor), both of which are AU-rich element-binding proteins that interact with the TNFα mRNA (62). In addition, Mnk1 phosphorylates Sprouty 2, a negative regulator of Erk signaling (63). The phosphorylation of Sprouty 2 by Mnk1 regulates its stability and prevents its degradation, providing an important control point for activation of the Erk pathway by FGFR (63). Additionally, Mnk1 has been shown to phosphorylate cytosolic phospholipase A2 on serine 727, resulting in its activation and subsequent arachidonate release (64). The potential regulation of such Mnk-controlled pathways by the IFNγ receptor and implications that such pathways may have in IFNγ-induced, Mnk-dependent, hematopoietic suppression remains to be directly examined in future studies. Nevertheless, independent of the identity of putative downstream effectors that may be involved in the process, our data suggest a central role for this kinase in myelosuppression. Beyond its involvement in Type I (60) and II IFN signaling, Mnk activity is essential for mRNA translation of the gene for TNFα (62), a cytokine that exhibits potent myelosuppressive effects (65, 66). Thus, it is possible that, as is the case for p38 MAPK (17, 25, 66–68), Mnk is a central integrator of signals for the generation of myelosuppressive responses in the regulation of hematopoiesis. If this hypothesis proves to be correct, it would raise the possibility of studies to target this pathway for the treatment of bone marrow failure syndromes involving overproduction of myelosuppressive cytokines (50), and this should be addressed in future studies.

REFERENCES

1. Isaacs, A., and Lindemann, J. (1957) Proc. R. Soc. Lond. B Biol. Sci. 147, 258–267
2. Platanias, L. C. (2005) Nat. Rev. Immunol. 5, 375–386
3. Borden, E. C., Sen, G. C., Uze, G., Silverman, R. H., Ransohoff, R. M., Foster, G. R., and Hunter, T. (1997) EMBO J. 16, 1921–1933
4. Scheper, G. C., Morrice, N. A., Kleijn, M., and Proud, C. G. (2001) J. Biol. Chem. 276, 37634–37640
5. Kaur, S., Sassano, A., Kambhampati, S., Uddin, S., Rahman, A., Roy, S. K., Hu, J., Shapiro, P. S., Reddy, S. P., Platanias, L. C. (2003) J. Immunol. 171, 267–273
6. Verma, A., Deb, D. K., Sassano, A., Kambhampati, S., Wickrema, A., Uddin, S., Mohindru, M., Van Besien, K., and Platanias, L. C. (2002) J. Immunol. 168, 5984–5988
7. Horuchi, M., Itoh, A., Pleasure, D., and Itoh, T. (2006) J. Biol. Chem. 281, 20095–20106
8. Roy, S. K., Hu, J., Meng, Q., Xia, Y., Shapiro, P. S., Reddy, S. P., Platanias, L. C., Lindner, D. J., Johnson, P. F., Pritchard, C., Pagés, G., Pouyssegur, J., and Kalvakolanu, D. V. (2002) Proc. Natl. Acad. Sci. U.S.A. 99, 7945–7950
9. Salmenperä, P., Hämäläinen, S., Hukkanen, M., and Kankuri, E. (2003) Am. J. Physiol. Cell Physiol. 284, C1133–C1139
10. Fukunaga, R., and Hunter, T. (1997) EMBO J. 16, 1909–1920
11. Waskiewicz, A. J., Flynn, A., Proud, C. G., and Cooper, J. A. (1997) EMBO J. 16, 1909–1920
12. Uddin, S., Lekmine, F., Sharma, N., Majchrzak, B., Mayer, I., Young, P. R., Bokoch, G. M., Fish, E. N., and Platanias, L. C. (2000) J. Biol. Chem. 275, 27634–27640
13. Kaur, S., Sassano, A., Joseph, A. M., Majchrzak-Kita, B., Ecklund, E. A., Verma, A., Brachmann, S. M., Fish, E. N., and Platanias, L. C. (2008) J. Immunol. 181, 7316–7323
14. Uddin, S., Yenush, L., Sun, X. J., Sweet, M. E., White, M. F., and Platanias, L. C. (1995) J. Biol. Chem. 270, 15938–15941
15. Ahmad, S., Alsayed, Y. M., Druker, B. J., and Platanias, L. C. (1997) J. Biol. Chem. 272, 29991–29994
16. Verma, A., Deb, D. K., Sassano, A., Uddin, S., Varga, J., Wickrema, A., and Platanias, L. C. (2002) J. Biol. Chem. 277, 7726–7735
17. Horvai, A. E., Xu, L., Korzus, E., Brand, G., Kalafus, D., Mullen, T. M., Rose, D. W., Rosenfeld, M. G., and Glass, C. K. (1997) Proc. Natl. Acad. Sci. U.S.A. 94, 1074–1079
18. Mayer, I. A., Verma, A., Grumbach, I. M., Uddin, S., Lekmine, F., Ravandi, F., Majchrzak, B., Fujita, S., Fish, E. N., and Platanias, L. C. (2001) J. Biol. Chem. 276, 28570–28577
19. Borden, E. C., Sen, G. C., Uze, G., Silverman, R. H., Ransohoff, R. M., Foster, G. R., and Stark, G. R. (2007) Nat. Rev. Drug Discov. 6, 975–990
20. Schoenborn, J. R., and Wilson, C. B. (2007) Adv. Immunol. 96, 41–101
21. Kaur, S., Lal, A., Kolluri, R. K., Redig, S. R., and Platanias, L. C. (2008) J. Biol. Chem. 283, 12034–12042
22. Wang, X., Flynn, A., Waskiewicz, A. J., Webb, B. L., Vries, R. G., Baines, I. A., Cooper, J. A., and Proud, C. G. (1998) J. Biol. Chem. 273, 9373–9377
23. Waskiewicz, A. J., Johnson, J. C., Penn, B., Mahalingam, M., Kimball, S. R., and Cooper, J. A. (1999) Mol. Cell. Biol. 19, 1871–1880
24. Schepers, G. C., Morrice, N. A., Kleijn, M., and Proud, C. G. (2001) Mol. Cell. Biol. 21, 743–754
25. Ueda, T., Watanabe-Fukunaga, R., Fukuyama, H., Nagata, S., and Fukunaga, R. (2004) Mol. Cell. Biol. 24, 6539–6549
26. Meng, Q., Raha, A., Roy, S., Hu, J., and Kalvakolanu, D. V. (2005) J. Immunol. 174, 6203–6211
27. Valledor, A. F., Sánchez-Tilló, E., Arpa, L., Park, J. M., Caelles, C.,
Mnk Kinases in the Generation of IFNγ Responses

Lloberas, J., and Celada, A. (2008) J. Immunol. 180, 4523–4529
37. Buxade, M., Parra-Palau, J. L., and Proud, C. G. (2008) Front. Biosci. 13, 5359–5373
38. Flynn, A., and Proud, C. G. (2008) Front. Biosci. 13, 5359–5373
39. Ishida, M., Ishida, T., Nakashima, H., Miho, N., Miyagawa, K., Chayama, K., Oshima, T., Kambe, M., and Yoshizumi, M. (2003) Circ. Res. 93, 1218–1224
40. Wheater, M. J., Johnson, P. W., and Blaydes, J. P. (2010) Cancer Biol. Ther. 10, 728–735
41. Bianchini, A., Loiarro, M., Bielli, P., Busa, R., Paronetto, M. P., Loreni, F., Geremia, R., and Sette, C. (2008) Carcinogenesis 29, 2279–2288
42. Andersson, K., and Sundler, R. (2006) Cytokine 33, 52–57
43. Rowlett, R. M., Chrestensen, C. A., Nyce, M., Harp, M. G., Pelo, J. W., Cominelli, F., Ernst, P. B., Pizarro, T. T., Sturgill, T. W., and Worthington, M. T. (2008) Am. J. Physiol. Gastrointest. Liver Physiol. 294, G452–G459
44. Goetz, C., Everson, R. G., Zhang, L. C., and Gromeier, M. (2010) Mol. Ther. 18, 1937–1946
45. Furic, L., Rong, L., Larsson, O., Koumakpayi, I. H., Yoshida, K., Brueeschke, A., Petroulakis, E., Robichaud, N., Pollak, M., Gaboury, L. A., Pandolfi, P. P., Saad, F., and Sonenberg, N. (2010) Proc. Natl. Acad. Sci. U.S.A. 107, 14134–14139
46. Miller, C. H., Maher, S. G., and Young, H. A. (2009) Ann. N.Y. Acad. Sci. 1182, 69–79
47. Hefner, Y., Borsch-Haubold, A. G., Murakami, M., Wilde, J. I., Pasquet, S., Schieltz, D., Ghomashchi, F., Yates, J. R., 3rd, Armstrong, C. G., Paterson, A., Cohen, P., Fukunaga, R., Hunter, T., Kudo, I., Watson, S. P., and Gelb, M. H. (2000) J. Biol. Chem. 275, 37542–37551
48. Broxmeyer, H. E., Williams, D. E., Lu, L., Cooper, S., Anderson, S. L., Beyer, G. S., Hoffman, R., and Rubin, B. Y. (1986) J. Immunol. 136, 4487–4495
49. Matsoulidis, E., Li, Y., Yoon, P., Sassano, A., Altman, J., Kannan-Thulasiraman, P., Balasubramanian, L., Parmar, S., Varga, J., Tallman, M. S., Verma, A., and Platanias, L. C. (2005) Cancer Res. 65, 9029–9037
50. Platanias, L. C. (2003) Pharmcol. Ther. 98, 129–142
51. Platanias, L. C. (2003) Blood 101, 4667–4679